BAILEY SHREDL: Open Payments
NPI 1508539891 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,908 in 91 payments from 37 companies in 2025. Trend: 2023 $1,477 · 2024 $2,567 · 2025 $1,908
Food & beverage: $1,908
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. | 8 | $177 |
| Janssen Biotech, Inc. | 9 | $176 |
| Novartis Pharmaceuticals Corporation | 7 | $155 |
| AstraZeneca Pharmaceuticals LP | 6 | $113 |
| Regeneron Healthcare Solutions, Inc. | 4 | $109 |
| PFIZER INC. | 4 | $73 |
| TerSera Therapeutics LLC | 2 | $68 |
| Eisai Inc. | 3 | $67 |
| Geron Corporation | 3 | $66 |
| ABBVIE INC. | 3 | $62 |
Products named: LIBTAYO, KISQALI, Lenvima, RYTELO, Enhertu, KEYTRUDA, Tecentriq, DARZALEX.
Industry payments across MO — which companies pay providers there.
